CervoMed News and Activities

CervoMed is a company listed under the stock ticker CRVO (US).

View the org chart displaying its 15 main executives

Most searched biographies at CervoMed

• John Alam, Chief Executive Officer
• Frank Zavrl, Director
• David Quigley, Director

Popular executive movements at CervoMed

• David Quigley has joined the company as Director  (posted on October 28 2025).
• Matthew Winton has joined the company as Chief Commercial and Business Officer  (posted on October 7 2025).

Create your alert
to follow the executive moves at CervoMed.

CervoMed has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
• Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott

Learn more about the Pharmaceuticals industry

Press releases by CervoMed

• CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates | CervoMed
• CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies | CervoMed
• CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting | CervoMed
• CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates | CervoMed
• CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology | CervoMed
• CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference | CervoMed
• CervoMed to Participate in Upcoming Investor Conferences | CervoMed
• CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies | CervoMed
• CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis | CervoMed
• CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) | CervoMed
• View more press releases Close

Social media about CervoMed

• CervoMed on Wikipedia, Google News & Yahoo Finance
• CervoMed on LinkedIn, X (Twitter) & YouTube